AI Article Synopsis
- * It consists of sulbactam, a penicillin derivative that's effective against certain bacteria but is often broken down by β-lactamases, and durlobactam, which inhibits these enzymes and helps restore sulbactam's efficacy.
- * This combination offers a potential new treatment option for serious infections, especially those caused by multidrug-resistant bacteria, which can lead to high mortality rates.
Article Abstract
Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination that has been approved by the US FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of complex (ABC) in patients 18 years of age and older. Sulbactam is a penicillin derivative with antibacterial activity against but is prone to hydrolysis by β-lactamases encoded by contemporary isolates. Durlobactam is a diazabicyclooctane β-lactamase inhibitor with activity against Ambler classes A, C and D serine β-lactamases that restores sulbactam activity both and against multidrug-resistant ABC. Sulbactam-durlobactam is a promising alternative therapy for the treatment of serious infections, which can have high rates of mortality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229585 | PMC |
| http://dx.doi.org/10.2217/fmb-2023-0248 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!